Six core targets (TP53, CCND1, IL-1β, etc.) were identified. Molecular docking and in vitro experiments confirmed that matrine upregulates TP53 while downregulating CCND1 and IL1B, effectively inhibiting cancer cell proliferation and migration while mitigating inflammatory responses. The gene discussed is TP53; the disease is cancer.